Sabby Management buys $4,633,555 stake in Dynavax Technologies Corporation (DVAX)

Dynavax Technologies Corporation (DVAX) : Sabby Management scooped up 70,505 additional shares in Dynavax Technologies Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 290,505 shares of Dynavax Technologies Corporation which is valued at $4,633,555.Dynavax Technologies Corporation makes up approximately 1.53% of Sabby Management’s portfolio.

Other Hedge Funds, Including , Lombard Odier Asset Management (usa) Corp boosted its stake in DVAX in the latest quarter, The investment management firm added 18,221 additional shares and now holds a total of 214,090 shares of Dynavax Technologies Corporation which is valued at $3,414,736. Dynavax Technologies Corporation makes up approx 0.45% of Lombard Odier Asset Management (usa) Corp’s portfolio.Alpine Partners Vi boosted its stake in DVAX in the latest quarter, The investment management firm added 3,000 additional shares and now holds a total of 13,000 shares of Dynavax Technologies Corporation which is valued at $207,350. Dynavax Technologies Corporation makes up approx 0.09% of Alpine Partners Vi’s portfolio. Perceptive Advisors added DVAX to its portfolio by purchasing 2,499 company shares during the most recent quarter which is valued at $39,859.Wfg Advisors Lp reduced its stake in DVAX by selling 482 shares or 88.12% in the most recent quarter. The Hedge Fund company now holds 65 shares of DVAX which is valued at $1,037.

Dynavax Technologies Corporation opened for trading at $15.75 and hit $16.03 on the upside on Thursday, eventually ending the session at $15.94, with a gain of 1.79% or 0.28 points. The heightened volatility saw the trading volume jump to 4,16,746 shares. Company has a market cap of $614 M.

On the company’s financial health, Dynavax Technologies Corporation reported $-0.75 EPS for the quarter, missing the analyst consensus estimate by $ -0.06 based on the information available during the earnings call on Aug 5, 2016. Analyst had a consensus of $-0.69. The company had revenue of $2.65 million for the quarter, compared to analysts expectations of $1.58 million. The company’s revenue was up 70.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.80 EPS.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are organized under three areas of focus: vaccine adjuvants cancer immunotherapy and autoimmune and inflammatory diseases. The Company’s pipeline of product candidates includes HEPLISAV-B an investigational adult hepatitis B vaccine is in Phase III clinical trials; SD-101 a cancer immunotherapy candidate is in Phase I/II clinical trials; AZD1419 a candidate drug for asthma is in Phase II clinical trials planning; DV1179 is an inhibitor of TLR 7 and TLR 9 for autoimmune and inflammatory diseases is in Phase I clinical trials. DV230-Nanoparticle is a second generation adjuvant. DV230-Nanoparticle is in preclinical stage.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *